Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

NCT01805271 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1278

Enrollment

OTHER

Sponsor class

Conditions

Primary Non-metastatic Breast Cancer
Who Remain Disease-free

Interventions

DRUG: Everolimus
DRUG: Placebo

Sponsor

UNICANCER

Collaborators

[object Object]